SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Aclaris Therapeutics, Inc. – ‘10-K’ for 12/31/23 – ‘EX-97.1’

On:  Tuesday, 2/27/24, at 7:30am ET   ·   For:  12/31/23   ·   Accession #:  1558370-24-1753   ·   File #:  1-37581

Previous ‘10-K’:  ‘10-K’ on 2/23/23 for 12/31/22   ·   Latest ‘10-K’:  This Filing   ·   18 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/27/24  Aclaris Therapeutics, Inc.        10-K       12/31/23   91:11M                                    Toppan Merrill Bridge/FA

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.68M 
 2: EX-4.1      Instrument Defining the Rights of Security Holders  HTML     38K 
 3: EX-10.15    Material Contract                                   HTML    117K 
 4: EX-10.18    Material Contract                                   HTML     86K 
 5: EX-10.22    Material Contract                                   HTML     38K 
 6: EX-21.1     Subsidiaries List                                   HTML     26K 
 7: EX-23.1     Consent of Expert or Counsel                        HTML     24K 
11: EX-97.1     Clawback Policy re: Recovery of Erroneously         HTML     45K 
                Awarded Compensation                                             
 8: EX-31.1     Certification -- §302 - SOA'02                      HTML     29K 
 9: EX-31.2     Certification -- §302 - SOA'02                      HTML     28K 
10: EX-32.1     Certification -- §906 - SOA'02                      HTML     28K 
17: R1          Document and Entity Information                     HTML     94K 
18: R2          Consolidated Balance Sheets                         HTML    125K 
19: R3          Consolidated Balance Sheets (Parenthetical)         HTML     44K 
20: R4          Consolidated Statements of Operations and           HTML    118K 
                Comprehensive Loss                                               
21: R5          Consolidated Statements of Operations and           HTML     27K 
                Comprehensive Loss (Parenthetical)                               
22: R6          Consolidated Statements of Stockholders' Equity     HTML     85K 
23: R7          Consolidated Statements of Stockholders' Equity     HTML     28K 
                (Parenthetical)                                                  
24: R8          Consolidated Statements of Cash Flows               HTML    101K 
25: R9          Organization and Nature of Business                 HTML     33K 
26: R10         Summary of Significant Accounting Policies          HTML     72K 
27: R11         Fair Value of Financial Assets and Liabilities      HTML    191K 
28: R12         Property and Equipment, Net                         HTML     44K 
29: R13         Intangible Assets                                   HTML     61K 
30: R14         Accrued Expenses                                    HTML     41K 
31: R15         Debt                                                HTML     31K 
32: R16         Stockholders' Equity                                HTML     39K 
33: R17         Stock-Based Awards                                  HTML    166K 
34: R18         Net Loss per Share                                  HTML     64K 
35: R19         Leases                                              HTML     97K 
36: R20         Income Taxes                                        HTML    130K 
37: R21         Agreements Related to Intellectual Property         HTML     36K 
38: R22         Retirement Savings Plan                             HTML     27K 
39: R23         Restructuring Charges                               HTML     29K 
40: R24         Segment Information                                 HTML    132K 
41: R25         Legal Proceedings                                   HTML     28K 
42: R26         Summary of Significant Accounting Policies          HTML    121K 
                (Policies)                                                       
43: R27         Fair Value of Financial Assets and Liabilities      HTML    192K 
                (Tables)                                                         
44: R28         Property and Equipment, Net (Tables)                HTML     43K 
45: R29         Intangible Assets (Tables)                          HTML     62K 
46: R30         Accrued Expenses (Tables)                           HTML     40K 
47: R31         Stock-Based Awards (Tables)                         HTML    164K 
48: R32         Net Loss per Share (Tables)                         HTML     65K 
49: R33         Leases (Tables)                                     HTML     98K 
50: R34         Income Taxes (Tables)                               HTML    128K 
51: R35         Segment Information (Tables)                        HTML    127K 
52: R36         Organization and Nature of Business (Details)       HTML     31K 
53: R37         Summary of Significant Accounting Policies          HTML     36K 
                (Details)                                                        
54: R38         Summary of Significant Accounting Policies -        HTML     34K 
                Property and Equipment (Details)                                 
55: R39         Summary of Significant Accounting Policies -        HTML     31K 
                Intangible Assets (Details)                                      
56: R40         Summary of Significant Accounting Policies -        HTML     33K 
                Stock-Based Compensation and Concentration of                    
                Credit Risk and of Significant Suppliers (Details)               
57: R41         Summary of Significant Accounting Policies -        HTML     26K 
                Segments (Details)                                               
58: R42         Fair Value of Financial Assets and Liabilities      HTML     54K 
                (Details)                                                        
59: R43         Fair Value of Financial Assets and Liabilities -    HTML     64K 
                By Type of Security (Details)                                    
60: R44         Property and Equipment, Net (Details)               HTML     44K 
61: R45         Intangible Assets (Details)                         HTML     44K 
62: R46         Intangible Assets - Future Amortization Expenses    HTML     40K 
                (Details)                                                        
63: R47         Accrued Expenses (Details)                          HTML     38K 
64: R48         Debt (Details)                                      HTML     43K 
65: R49         Stockholders' Equity (Details)                      HTML     60K 
66: R50         Stockholders' Equity - Other Offerings and ATM      HTML     46K 
                Facility (Details)                                               
67: R51         Stock-Based Awards (Details)                        HTML     72K 
68: R52         Stock-Based Awards - Option Activity (Details)      HTML     84K 
69: R53         Stock-Based Awards - RSUs (Details)                 HTML     51K 
70: R54         Stock-Based Awards - Compensation (Details)         HTML     45K 
71: R55         Net Loss per Share (Details)                        HTML     56K 
72: R56         Net Loss per Share - Anti-dilution (Details)        HTML     32K 
73: R57         Leases (Details)                                    HTML     54K 
74: R58         Leases - Lease Costs (Details)                      HTML     26K 
75: R59         Leases - Supplemental Information Related to        HTML     36K 
                Operating Leases (Details)                                       
76: R60         Leases - Future Maturities of Lease Liabilities     HTML     43K 
                (Details)                                                        
77: R61         Income Taxes - Rate Reconciliation (Details)        HTML     64K 
78: R62         Income Taxes - Deferred Assets and Liabilities,     HTML     76K 
                CFDs (Details)                                                   
79: R63         Income Taxes - Valuation Allowance and              HTML     31K 
                Unrecognized Tax Benefits (Details)                              
80: R64         Agreements Related to Intellectual Property         HTML     53K 
                (Details)                                                        
81: R65         Retirement Savings Plan (Details)                   HTML     28K 
82: R66         Restructuring Charges (Details)                     HTML     43K 
83: R67         Segment Information (Details)                       HTML     65K 
84: R68         Legal Proceedings (Details)                         HTML     27K 
85: R69         Pay vs Performance Disclosure                       HTML     36K 
86: R70         Insider Trading Arrangements                        HTML     30K 
88: XML         IDEA XML File -- Filing Summary                      XML    155K 
91: XML         XBRL Instance -- acrs-20231231x10k_htm               XML   2.56M 
87: EXCEL       IDEA Workbook of Financial Report Info              XLSX    148K 
13: EX-101.CAL  XBRL Calculations -- acrs-20231231_cal               XML    187K 
14: EX-101.DEF  XBRL Definitions -- acrs-20231231_def                XML    602K 
15: EX-101.LAB  XBRL Labels -- acrs-20231231_lab                     XML   1.37M 
16: EX-101.PRE  XBRL Presentations -- acrs-20231231_pre              XML    938K 
12: EX-101.SCH  XBRL Schema -- acrs-20231231                         XSD    167K 
89: JSON        XBRL Instance as JSON Data -- MetaLinks              543±   818K 
90: ZIP         XBRL Zipped Folder -- 0001558370-24-001753-xbrl      Zip    593K 


‘EX-97.1’   —   Clawback Policy re: Recovery of Erroneously Awarded Compensation


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C:  <!  <> 

Exhibit 97.1

ACLARIS THERAPEUTICS, INC.

INCENTIVE COMPENSATION RECOUPMENT POLICY

1.INTRODUCTION

The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”), and the Board have determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of Recoverable Incentive Compensation that is received by Covered Officers of the Company under certain circumstances. Certain capitalized terms used in this Policy have the meanings given to such terms in Section 3 below.

This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder (“Rule 10D-1”) and Nasdaq Listing Rule 5608 (the “Listing Standards”).

2.EFFECTIVE DATE

This Policy shall apply to all Incentive Compensation that is received by a Covered Officer on or after October 2, 2023 (the “Effective Date”). Incentive Compensation is deemed “received” in the Company’s fiscal period in which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of such Incentive Compensation occurs after the end of that period.

3.DEFINITIONS

Accounting Restatement” means an accounting restatement that the Company is required to prepare due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.

Accounting Restatement Date” means the earlier to occur of (a) the date that the Board, a committee of the Board authorized to take such action, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date that a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.

Administrator” means the Compensation Committee or, in the absence of such committee, the Board.

Code” means the U.S. Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.

Covered Officer” means each current and former Executive Officer.

Exchange” means the Nasdaq Stock Market.

Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended.


Executive Officer” means the Company’s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company’s parent(s) or subsidiaries are deemed executive officers of the Company if they perform such policy-making functions for the Company. Policy-making function is not intended to include policy-making functions that are not significant. Identification of an executive officer for purposes of this Policy would include at a minimum executive officers identified pursuant to Item 401(b) of Regulation S-K promulgated under the Exchange Act.

Financial Reporting Measures” means measures that are determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measures derived wholly or in part from such measures, including Company stock price and total shareholder return (“TSR”). A measure need not be presented in the Company’s financial statements or included in a filing with the SEC in order to be a Financial Reporting Measure.

Incentive Compensation” means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.

Lookback Period” means the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (resulting from a change in the Company’s fiscal year) within or immediately following those three completed fiscal years (except that a transition period of at least nine months shall count as a completed fiscal year). Notwithstanding the foregoing, the Lookback Period shall not include fiscal years completed prior to the Effective Date.

Recoverable Incentive Compensation” means Incentive Compensation received by a Covered Officer during the Lookback Period that exceeds the amount of Incentive Compensation that would have been received had such amount been determined based on the Accounting Restatement, computed without regard to any taxes paid (i.e., on a gross basis without regarding to tax withholdings and other deductions). For any compensation plans or programs that take into account Incentive Compensation, the amount of Recoverable Incentive Compensation for purposes of this Policy shall include, without limitation, the amount contributed to any notional account based on Recoverable Incentive Compensation and any earnings to date on that notional amount. For any Incentive Compensation that is based on stock price or TSR, where the Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Administrator will determine the amount of Recoverable Incentive Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive Compensation was received. The Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the Exchange in accordance with the Listing Standards.

SEC” means the U.S. Securities and Exchange Commission.

4.RECOUPMENT

(a)Applicability of Policy. This Policy applies to Incentive Compensation received by a Covered Officer (i) after beginning services as an Executive Officer, (ii) who served as an Executive Officer at any time during the performance period for such Incentive Compensation, (iii) while the Company had a class of securities listed on a national securities exchange or a national securities association, and (iv) during the Lookback Period.

(b)Recoupment Generally.  Pursuant to the provisions of this Policy, if there is an

2


Accounting Restatement, the Company must reasonably promptly recoup the full amount of the Recoverable Incentive Compensation, unless the conditions of one or more subsections of Section 4(c) of this Policy are met and the Compensation Committee, or, if such committee does not consist solely of independent directors, a majority of the independent directors serving on the Board, has made a determination that recoupment would be impracticable. Recoupment is required regardless of whether the Covered Officer engaged in any misconduct and regardless of fault, and the Company’s obligation to recoup Recoverable Incentive Compensation is not dependent on whether or when any restated financial statements are filed.

(c)Impracticability of Recovery. Recoupment may be determined to be impracticable if, and only if:

(i)the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of the applicable Recoverable Incentive Compensation; provided that, before concluding that it would be impracticable to recover any amount of Recoverable Incentive Compensation based on expense of enforcement, the Company shall make a reasonable attempt to recover such Recoverable Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange in accordance with the Listing Standards; or

(ii)recoupment of the applicable Recoverable Incentive Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Code Section 401(a)(13) or Code Section 411(a) and regulations thereunder.

(d)Sources of Recoupment.  To the extent permitted by applicable law, the Administrator shall, in its sole discretion, determine the timing and method for recouping Recoverable Incentive Compensation hereunder, provided that such recoupment is undertaken reasonably promptly. The Administrator may, in its discretion, seek recoupment from a Covered Officer from any of the following sources or a combination thereof, whether the applicable compensation was approved, awarded, granted, payable or paid to the Covered Officer prior to, on or after the Effective Date: (i) direct repayment of Recoverable Incentive Compensation previously paid to the Covered Officer; (ii) cancelling prior cash or equity-based awards (whether vested or unvested and whether paid or unpaid); (iii) cancelling or offsetting against any planned future cash or equity-based awards; (iv) forfeiture of deferred compensation, subject to compliance with Code Section 409A; and (v) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Administrator may effectuate recoupment under this Policy from any amount otherwise payable to the Covered Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, e.g., base salary, bonuses or commissions and compensation previously deferred by the Covered Officer. The Administrator need not utilize the same method of recovery for all Covered Officers or with respect to all types of Recoverable Incentive Compensation.

(e)No Indemnification of Covered Officers. Notwithstanding any indemnification agreement, applicable insurance policy or any other agreement or provision of the Company’s certificate of incorporation or bylaws to the contrary, no Covered Officer shall be entitled to indemnification or advancement of expenses in connection with any enforcement of this Policy by the Company, including paying or reimbursing such Covered Officer for insurance premiums to cover potential obligations to the Company under this Policy.

(f)Indemnification of Administrator. Any members of the Administrator, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be indemnified by the

3


Company to the fullest extent under applicable law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy.

5.ADMINISTRATION

Except as specifically set forth herein, this Policy shall be administered by the Administrator. The Administrator shall have full and final authority to make any and all determinations required under this Policy.  Any determination by the Administrator with respect to this Policy shall be final, conclusive and binding on all interested parties and need not be uniform with respect to each individual covered by this Policy. In carrying out the administration of this Policy, the Administrator is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee’s responsibility and authority. Subject to applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions that the Administrator, in its sole discretion, deems necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee).

6.SEVERABILITY

If any provision of this Policy or the application of any such provision to a Covered Officer shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.

7.NO IMPAIRMENT OF OTHER REMEDIES

Nothing contained in this Policy, and no recoupment or recovery as contemplated herein, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Officer arising out of or resulting from any actions or omissions by the Covered Officer. This Policy does not preclude the Company from taking any other action to enforce a Covered Officer’s obligations to the Company, including, without limitation, termination of employment and/or institution of civil proceedings. This Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 that are applicable to the Company’s Chief Executive Officer and Chief Financial Officer and to any other compensation recoupment policy and/or similar provisions in any employment, equity plan, equity award, or other individual agreement, to which the Company is a party or which the Company has adopted or may adopt and maintain from time to time.

8.AMENDMENT; TERMINATION

The Administrator may amend, terminate or replace this Policy or any portion of this Policy at any time and from time to time in its sole discretion. The Administrator shall amend this Policy as it deems necessary to comply with applicable law or any Listing Standard.

9.SUCCESSORS

This Policy shall be binding and enforceable against all Covered Officers and, to the extent required by Rule 10D-1 and/or the applicable Listing Standards, their beneficiaries, heirs, executors, administrators or other legal representatives.

4


10.REQUIRED FILINGS

The Company shall make any disclosures and filings with respect to this Policy that are required by law, including as required by the SEC.

*          *          *          *          *

5


ACLARIS THERAPEUTICS, INC.

INCENTIVE COMPENSATION RECOUPMENT POLICY

FORM OF EXECUTIVE ACKNOWLEDGMENT

I, the undersigned, agree and acknowledge that I am bound by, and subject to, the Aclaris Therapeutics, Inc. Incentive Compensation Recoupment Policy, as may be amended, restated, supplemented or otherwise modified from time to time (the “Policy”). In the event of any inconsistency between the Policy and the terms of any employment agreement, offer letter or other individual agreement with Aclaris Therapeutics, Inc. (the “Company”) to which I am a party, or the terms of any compensation plan, program or agreement, whether or not written, under which any compensation has been granted, awarded, earned or paid to me, the terms of the Policy shall govern.

In the event that the Administrator (as defined in the Policy) determines that any compensation granted, awarded, earned or paid to me must be forfeited or reimbursed to the Company pursuant to the Policy, I will promptly take any action necessary to effectuate such forfeiture and/or reimbursement. I further agree and acknowledge that I am not entitled to indemnification, and hereby waive any right to advancement of expenses, in connection with any enforcement of the Policy by the Company.

Agreed and Acknowledged:

Name:

Title:

Date:



Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:2/27/248-K
For Period end:12/31/23
10/2/23
 List all Filings 


1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/25/24  Aclaris Therapeutics, Inc.        DEF 14A     6/06/24   11:3.3M                                   Toppan Merrill Bridge/FA


17 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/07/23  Aclaris Therapeutics, Inc.        10-Q        6/30/23   69:7.5M                                   Toppan Merrill Bridge/FA
 6/12/23  Aclaris Therapeutics, Inc.        8-K:5,9     6/09/23   11:292K                                   Toppan Merrill Bridge/FA
 6/01/23  Aclaris Therapeutics, Inc.        8-K:1,9     5/26/23   11:894K                                   Toppan Merrill Bridge/FA
 5/08/23  Aclaris Therapeutics, Inc.        10-Q        3/31/23   67:6.4M                                   Toppan Merrill Bridge/FA
 2/23/23  Aclaris Therapeutics, Inc.        10-K       12/31/22   88:11M                                    Toppan Merrill Bridge/FA
 2/23/23  Aclaris Therapeutics, Inc.        8-K:1,9     2/23/23   12:512K                                   Toppan Merrill/FA
 8/03/22  Aclaris Therapeutics, Inc.        10-Q        6/30/22   72:7.6M                                   Toppan Merrill Bridge/FA
 2/24/22  Aclaris Therapeutics, Inc.        10-K       12/31/21   98:12M                                    Toppan Merrill Bridge/FA
 6/24/20  Aclaris Therapeutics, Inc.        8-K:5,9     6/23/20    2:181K                                   Toppan Merrill Bridge/FA
 3/18/19  Aclaris Therapeutics, Inc.        10-K       12/31/18   97:13M                                    Toppan Merrill Bridge/FA
11/07/17  Aclaris Therapeutics, Inc.        10-Q        9/30/17   68:7.8M                                   Toppan Merrill Bridge/FA
 8/01/17  Aclaris Therapeutics, Inc.        8-K:5,9     7/31/17    4:479K                                   Toppan Merrill Bridge/FA
10/15/15  Aclaris Therapeutics, Inc.        S-8        10/15/15    4:391K                                   Toppan Merrill/FA
10/13/15  Aclaris Therapeutics, Inc.        8-K:5      10/13/15    3:240K                                   Toppan Merrill/FA
 9/25/15  Aclaris Therapeutics, Inc.        S-1/A                 15:4.9M                                   Toppan Merrill-FA
 9/04/15  Aclaris Therapeutics, Inc.        S-1/A                  7:4.5M                                   Toppan Merrill-FA
 8/17/15  Aclaris Therapeutics, Inc.        S-1                   14:6.1M                                   Toppan Merrill-FA
Top
Filing Submission 0001558370-24-001753   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 1, 7:28:41.2am ET